Creative Commons License: Image by Flickr user nikongirl1969)

The 10 Trends Transforming the Pharma Supply Chain

This post has already been read 19337 times!

Creative Commons License: Image by Flickr user nikongirl1969)

The pharmaceutical landscape continues to morph at a rapid pace, and participating companies are having to develop ever more sophisticated supply chain processes and strategies in order to deal with ongoing changes in demographics, urban migration, increasing demand for healthcare, shifts toward age related disease patterns, and a rising health awareness across the population.

Today is the first in a series of posts that explores what are in my opinion the ten most significant trends that are transforming the pharmaceutical supply chain. Today we’ll cover the first two:

Number 1: The Rise of OTC and Generics

The market for Over-the-Counter (OTC) medicines is now forecast to outgrow the total current pharmaceutical market. World revenue for OTC medicines could reach $80B US by the end of 2014, supported by the trend for drugs to move from prescription to OTC.

Competition from generics coupled with pressure from expiring patents have flattened or decreased the top-line potential of many branded pharmaceutical business units.
It is estimated that $220B in sales are at risk from patent expirations between 2013 and 2018.

From a supply chain perspective this means that like most other industries today, pharmaceutical distribution channels must address the increased usage of online ordering and direct-to-customer delivery processes.

Number 2: The Growing Demand for S&OP

Given the pharmaceuticals industry’s various challenges already described above, the notion of leveraging a next generation sales and operations planning capability should be a strong consideration for every pharmaceutical company.

However deploying this type of advanced design has been difficult to date due to the lack of a platform that can enable consensus based collaborative forecasting and planning across the highly regulated networks. Pharmaceuticals has been slow to adopt these types of advanced platforms due to its skepticism of cloud based solutions and the security related to shared data.

Technology vendors have made significant progress in permission based access and data level security causing supply chain leaders to reevaluate the deployment of a cloud-based planning layer over their core enterprise systems. Properly implemented and designed, a cloud-based planning layer enables the sharing of S&OP data across key stakeholders: contract manufacturers, branded and generic business units, distributors, and retailers.This planning layer enables collaborative and iterative simulation planning that takes into consideration pertinent factors such as current demand, projected sales scenarios and supply constraints like lead time and capacity.

Once consensus has been achieved on the forecast and the upstream planning of materials and capacity have been agreed to by all concerned stakeholders (for example, the brand owner and its contract manufacturers), the plan can then be adopted by the respective ERP systems to generate lower-level planning like MPS or MRP. In more advanced implementations the cloud platform can be deployed at the execution layer as well, eliminating the need to integrate across multiple ERP silos. The added benefit in the advanced case is the significant reduction of lead times across the
pharmaceutical supply network.

I started to take Phentermine in 2015. As was written in the instruction at, the main component affected the center of hunger in the brain and was absolutely effective. As for the side effects, I experienced bad sleep, terrible hand tremor, constantly bad and depressed mood, attacks of aggression.

The core of this platform shift resides in the master data model and associated data warehouse. The platform contains a deep and rich data model which represents data globally across all underlying systems, empowering both the advanced S&OP functions as well as supporting data and decision integration back into the ERP environment. This allows the supply network to be easily rolled out to multiple sites within the enterprise and also adopted by new suppliers and customers.

However just solving the pharmaceutical S&OP problem is only half the equation. Companies must also consider the full supply network related to executing operations, logistics, and distribution as well.

In future posts we’ll work through the remaining trends, but if you can’t wait I suggest you download the new whitepaper, The Top Ten Trends Transforming the Pharmaceutical Supply Chain.